Trustworthy medical team
At the Hemato-Oncology Center of Seoul National University Cancer Hospital, we are dedicated to treating not only hematologic cancers such as acute and chronic leukemia, multiple myeloma, malignant lymphoma, myelodysplastic syndromes, and myeloproliferative disorders, but also various blood diseases including aplastic anemia, deficiency anemias, hemolytic anemia, hemophilia, and coagulation disorders. The Hemato-Oncology Center at Seoul National University Cancer Hospital strives to achieve optimal treatment outcomes for complex hematologic cancers and blood disorders through collaboration with leading experts in related fields. Precise diagnosis and assessment of treatment response are paramount, and to this end, we closely cooperate with departments of diagnostic Laboratory Medicine, Nuclear Medicine, Radiology, and Pathology. Our center is equipped with the nation's top-tier blood bank, cellular immunology lab, genetic testing facilities, and hematopoietic stem cell transplantation units. Building upon this infrastructure, we offer personalized genomic testing services for hematologic cancers, facilitating tailored cancer treatments and clinical trials for new drugs. Our advanced treatments include various cellular therapies using blood and cell products, such as therapeutic leukapheresis, donor lymphocyte infusion, granulocyte infusion, CAR-T cell therapy, ex vivo cell-sorted transplantation, and cord blood/haploidentical transplantation.
World-class research-centered hospital
Recent advancements in the research of molecular targeted therapies and cellular therapies for hematologic cancers have been rapidly increasing, accompanied by a surge in clinical trials utilizing new drugs and technologies. In line with these developments, the Hemato-Oncology Center at Seoul National University Cancer Hospital is leading the way in hematologic cancer treatment research by conducting clinical trials with a variety of advanced new drugs and cellular therapies, including 'First in Human trials.' Moreover, since 2013, the center has been a contributing research institution for the hematologic genome sector in the International Cancer Genome Consortium (ICGC), the largest global collaborative research group in cancer genomics, which lays the foundation for personalized cancer treatment. The center also demonstrates leadership in multi-institutional studies conducted by various societies, such as the Korean Society of Hematology. Expanding opportunities for clinical trial participation to patients with recurrent or refractory hematologic cancers, who have limited options with conventional treatments, is part of our mission at Seoul National University Hospital's Hemato-Oncology Center. This approach not only offers a wide range of standard treatments but also enables these patients to seek improvement in their conditions through various innovative drugs and cellular therapies, reaffirming our position as a leading research-focused hospital globally.
Rich experience in hematopoietic stem cell transplantation
The Hematopoietic Stem Cell Transplantation Center at Seoul National University Hospital is the nation's leading transplant center, having performed more than 3000 hematopoietic stem cell transplants (adult patients) by the year 2023. This includes autologous stem cell transplants, sibling/unrelated allogeneic stem cell transplants, as well as second stem cell transplants, haploidentical transplants, cord blood transplants, and ex vivo cell-sorted transplants. The center has amassed extensive experience in these high-complexity hematopoietic stem cell transplants. In addition, it is the most experienced institution in cellular therapies such as donor lymphocyte infusion to prevent relapse post-transplant and granulocyte infusions to enhance survival in immunocompromised states. Furthermore, since 2022, the center has been at the forefront in South Korea in adopting CAR-T cell therapy, utilizing it innovatively for patient treatment. The hematopoietic stem cell transplants and various cellular therapies performed at Seoul National University Cancer Hospital's Hematopoietic Stem Cell Transplant Center not only offer hope of cure for patients with recurrent/refractory hematologic cancers, but they are also high-risk treatments. Therefore, a well-organized transplant center infrastructure and the medical team's vast experience are crucial. The Hematopoietic Stem Cell Transplantation team at Seoul National University Cancer Hospital is fully equipped with these essential resources.